Emergent Biosolutions, Inc. (NYSE:EBS) EVP Adam Havey sold 7,885 shares of Emergent Biosolutions stock in a transaction on Friday, September 8th. The stock was sold at an average price of $37.06, for a total value of $292,218.10. Following the completion of the sale, the executive vice president now directly owns 33,931 shares of the company’s stock, valued at approximately $1,257,482.86. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of Emergent Biosolutions, Inc. (NYSE:EBS) opened at 38.48 on Wednesday. The company has a market cap of $1.59 billion, a price-to-earnings ratio of 24.51 and a beta of 1.23. The firm has a 50 day moving average price of $35.94 and a 200-day moving average price of $32.40. Emergent Biosolutions, Inc. has a 12-month low of $24.47 and a 12-month high of $38.50.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.13). The business had revenue of $100.77 million for the quarter, compared to analyst estimates of $111.57 million. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.05) earnings per share. On average, equities analysts expect that Emergent Biosolutions, Inc. will post $1.54 earnings per share for the current fiscal year.
A number of research firms have commented on EBS. BidaskClub lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Zacks Investment Research lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $44.00.
Several hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio increased its position in shares of Emergent Biosolutions by 2.6% during the second quarter. Public Employees Retirement System of Ohio now owns 36,866 shares of the biopharmaceutical company’s stock worth $1,250,000 after purchasing an additional 917 shares in the last quarter. Piedmont Investment Advisors LLC acquired a new position in shares of Emergent Biosolutions during the second quarter worth $255,000. Ameritas Investment Partners Inc. increased its position in shares of Emergent Biosolutions by 23.2% during the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 587 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Emergent Biosolutions by 2.5% during the second quarter. The Manufacturers Life Insurance Company now owns 631,304 shares of the biopharmaceutical company’s stock worth $21,409,000 after purchasing an additional 15,314 shares in the last quarter. Finally, Macquarie Group Ltd. increased its position in shares of Emergent Biosolutions by 0.8% during the second quarter. Macquarie Group Ltd. now owns 25,969 shares of the biopharmaceutical company’s stock worth $881,000 after purchasing an additional 197 shares in the last quarter. 85.44% of the stock is currently owned by institutional investors and hedge funds.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.